TVGN
Tevogen Bio Holdings Inc (TVGN)
Healthcare • NASDAQ • $6.75+5.97%
- Symbol
- TVGN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.75
- Daily Change
- +5.97%
- Market Cap
- $28.99M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $49.50
- 52W Low
- $3.64
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.20
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; T…
Company websiteResearch TVGN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.